BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/1/2014 2:50:00 PM | Browse: 1292 | Download: 1515
 |
Received |
|
2013-06-03 11:13 |
|
Peer-Review Started |
|
2013-06-03 15:17 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
|
|
Revised |
|
|
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2013-06-18 11:01 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2013-06-19 00:45 |
|
Articles in Press |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2013-08-15 11:13 |
|
Publish the Manuscript Online |
|
2013-12-20 16:49 |
| Category |
Nutrition & Dietetics |
| Manuscript Type |
Topic Highlights |
| Article Title |
Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ahmadreza Moradi, Yasir Jamal Sepah, Mohammad Ali Sadiq, Humzah Nasir, Salima Kherani, Raafay Sophie, Diana V Do and Quan Dong Nguyen |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Quan Dong Nguyen, MD, MSc, Stanley M Truhlsen Eye Institute, University of Nebraska Medical Center, Emile St, Omaha, NE 68198, United States. quan.nguyen@unmc.edu |
| Key Words |
Diabetic macular edema; Diabetic retinopathy; Anti-vascular endothelial growth factor agents; Vascular endothelial growth factor trap-eye; Aflibercept; EYLEA |
| Core Tip |
Several different agents have been approved recently for the treatment of diabetic macular edema (DME). The index article outlines the role of aflibercept, an anti-vascular endothelial growth factor (VEGF) agent, as a potential therapeutic option. Results from DME trials with aflibercept have been favorable and comparable to other anti-VEGF agents. Because of its longer half-life, aflibercept may also decrease the frequency of injections for DME patients. These results could be attributed to the stronger and prolonged binding of aflibercept to the VEGF-A receptor compared to other available antagonists. A better understanding of the effect of this drug in DME is expected once the phase 3 trial results are available. |
| Publish Date |
2013-12-20 16:49 |
| Citation |
Moradi A, Sepah YJ, Sadiq MA, Nasir H, Kherani S, Sophie R, Do DV, Nguyen QD. Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema. World J Diabetes 2013; 4(6): 303-309 Available from: URL: http://www.wjgnet.com/1948-9358/full/v4/i6/303.htm DOI: http://dx.doi.org/10.4239/wjd.v4.i6.303 |
| URL |
http://www.wjgnet.com/1948-9358/full/v4/i6/303.htm |
| DOI |
http://dx.doi.org/10.4239/wjd.v4.i6.303 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
